Overview

A Study to Assess the Effects of Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid retaining effects of zibotentan can be mitigated by dapagliflozin.

Phase:

Phase 2

Details

Lead Sponsor:

University Medical Center Groningen

Collaborator:

AstraZeneca

Treatments:

Dapagliflozin